Additive Manufacturing Strategies

Organovo & Viscient Biosciences Collaborate for 3D Bioprinting in Liver Disease Research

ST Medical Devices

Share this Article

Earlier this month, both Organovo and Viscient Biosciences announced their intent to collaborate on research for further studies into liver disease. There have been many interesting stories about Organovo and their advances—from promises regarding 3D printed kidney and liver tissue for pharmaceutical testing to new data about extended survival and function in animal test subjects.

This latest partnership of Organovo’s will of course continue to build on all the research they have in place, much of which is centered around bioprinting. Viscient’s interests lie in research surrounding drug discovery efforts for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

“We continue to have excellent traction with a wide range of biopharmaceutical companies in evaluating our tissue systems to facilitate the discovery and development of novel drug candidates to treat liver disease. Our 3D disease models have the unique capability to demonstrate drug mechanisms of action and efficacy in a setting that closely mimics human livers,” said Taylor J. Crouch, CEO, Organovo.

“We’re proud to collaborate with Viscient’s talented team as they have a strong understanding of our expertise.  Our aim is to establish a custom platform that will support high-value drug profiling, and ultimately move our collaboration into a steady-state relationship.”

Such research is extremely important to the public, as around 100 million adults living in the US currently suffer from NAFLD, while an additional 20 million are living with NASH.

NAFLD is associated with inflammation, and an overload of fatty tissue in the liver. This important organ can be damaged, with lifelong consequences. As they collaborate, the hope is that Organovo and Viscient Biosciences will be able to create progressive and therapeutic treatments for NAFLD. Both conditions can lead to extremely serious illness, in the form of cirrhosis and cancer—and NASH is known as the second leading cause of liver transplants.

Organovo’s research is leading to many breakthroughs in studies regarding drug discovery, one of the greatest benefits of bioprinting. ExVive™ human liver and kidney tissues are used in the following:

  • Compound screening in disease models
  • Toxicology
  • Target and marker discovery/validation
  • Other types of drug testing

Non-alcoholic fatty liver disease

“Viscient is a strong believer in unlocking the power of 3D bioprinting to bring cures and treatments to patients with few options today,” said Keith Murphy, CEO, Viscient Biosciences. “In our pursuit of breakthrough therapies in important areas of medicine, we’re eager to tap into novel, complex and more accurate disease models. Organovo’s technology provides the potential for valuable and unprecedented insights as we target new drugs in areas of unmet medical need and strong commercial potential.

“Viscient’s plan goes arm and arm with Organovo,” Murphy said. “Viscient is going to be one of Organovo’s pharma customers.”

Headquartered in San Diego, Viscient is heavily involved in using 3D printing to make strides in drug development—and in fact, the company is comprised of former Organovo and Ardea Biosciences scientists and entrepreneurs. Find out more about them here.

Discuss this article and other 3D printing topics at 3DPrintBoard.com or share your thoughts below. 

[Sources / Images: XConomy: Globe NewsWire]

 

Share this Article


Recent News

FDM 3D Printing Support Removal Times Cut in Half with VORSA 500

3D Printing Drone Swarms, Part 12: 3D Printing Missiles



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

ICAM 2021: Keynotes on 3D Printing in Healthcare & Aerospace

At last month’s International Conference on Additive Manufacturing (ICAM) 2021 in Anaheim, California, hosted by ASTM International’s Additive Manufacturing Center of Excellence (AMCOE), a wide variety of topics were covered,...

Featured

3D Printing Unicorns: Gelato Gets $240M in Funding, Expands into 3D Printing

On-demand printing platform Gelato, based in Oslo, Norway, achieved the coveted unicorn status after a new funding round. On August 16, 2021, the company announced it had raised $240 million...

Featured

US Army and Raytheon to Use 3D Systems Metal 3D Printing to Heat-Optimize Munitions

3D Systems (NYSE: DDD) has been chosen by defense contractor Raytheon and the U.S. Army’s central laboratory to help with a design optimization project. To do that, the 3D Systems’...

Raytheon Receives Funding for Aerospace 3D Printing of Optical Components

This spring, Ohio-based America Makes, the leading collaborative partner in additive technology research, discovery, and innovation for the US, announced its latest Project Call for AXIOM, or  Additive for eXtreme Improvement...


Shop

View our broad assortment of in house and third party products.